Tofogliflozin
Based on 4 publication(s) in Google Scholar
Tofogliflozin (CSG-452) is a highly efficient and selective inhibitor of SGLT2, with Ki values of 2.9, 14.9 and 6.4nM for human, rat and mouse SGLT2 respectively.
For research use only. We do not sell to patients.
- Purity : 98.38%
- CAS No.: 903565-83-3
- Formula: C22H26O6
- Molecular Weight:386.44
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10450
DapagliflozinSGLT2 Inhibitor -
HY-15409
EmpagliflozinSGLT2 Inhibitor -
HY-10451
CanagliflozinSGLT2 Inhibitor -
HY-N0142
PhloretinAnti-inflammatory Agent -
HY-15516
SotagliflozinSGLT Inhibitor -
HY-14894
IpragliflozinSGLT Inhibitor -
HY-15461
ErtugliflozinSGLT2 Inhibitor -
HY-15461A
Ertugliflozin L-pyroglutamic acidSGLT2 Inhibitor -
HY-10450R
Dapagliflozin (Standard)SGLT2 Inhibitor -
HY-I0383
Canagliflozin hemihydrateSGLT Inhibitor -
HY-15409R
Empagliflozin (Standard)SGLT2 Inhibitor -
HY-10450A
Dapagliflozin ((2S)-1,2-propanediol, hydrate)SGLT2 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Tofogliflozin
More
Biological Activity
Description
IC50 & Target
|
SGLT2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
2.9 nM
Compound: 16d, CSG452, Tofogliflozin
|
Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
|
[PMID: 22889351] |
| CHO | IC50 |
8444 nM
Compound: 16d, CSG452, Tofogliflozin
|
Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
|
[PMID: 22889351] |
Chemical Information
-
CAS No. 903565-83-3
-
Appearance Solid
-
Molecular Weight 386.44
-
Formula C22H26O6
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@]21OCC3=CC=C(CC4=CC=C(CC)C=C4)C=C23
-
Synonyms
CSG452; R-7201
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. [Abstract]2018 Jun:152:45-59. PMID: 29551587 -
-
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous detection of 24 oral antidiabetic drugs and their metabolites in urine by liquid chromatography-tandem mass spectrometry. [Abstract]2020 Mar 15:1141:122020. PMID: 32062369 -
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31. [Content Brief]
[2]. Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2014 Oct 28:1-9. [Content Brief]
[3]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. [Content Brief]
[4]. Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tofogliflozin Related Classifications
HY-14902 Related Classifications
Powered by Bioz